Pfizer Inc. (PFE) filed a Form 8K - Entry Into a Definitive
Agreement - with the U.S Securities and Exchange Commission on
August 22, 2016.
On August 20, 2016, Pfizer Inc., a Delaware corporation
("Pfizer"), entered into an Agreement and Plan of Merger (the
"Merger Agreement") with Medivation, Inc., a Delaware corporation
("Medivation"), and Montreal, Inc., a Delaware corporation
("Purchaser") and a wholly owned subsidiary of Pfizer.
Pursuant to the Merger Agreement, and upon the terms and subject
to the conditions described therein, Pfizer will cause Purchaser to
commence a cash tender offer (the "Offer") within seven business
days following the date of the Merger Agreement to acquire all of
Medivation's outstanding shares of common stock, par value $0.01
per share (the "Medivation Stock"), for $81.50 per share, net to
the seller in cash, without interest, subject to any required
withholding of taxes (the "Offer Price"). The Offer will remain
open for a minimum of 20 business days from the date of
commencement.
The obligation of Purchaser to purchase shares of Medivation
Stock tendered in the Offer is subject to customary closing
conditions, including, among others, (i) shares of Medivation Stock
having been validly tendered and not validly withdrawn that
represent, together with the shares then owned by Pfizer and its
affiliates, at least a majority of the then-outstanding shares of
Medivation Stock, (ii) the expiration or termination of the waiting
period applicable to the Offer and the Merger (as defined below)
under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended, (iii) the absence of any injunction or other order issued
by a court of competent jurisdiction prohibiting the consummation
of the Offer or the Merger and (iv) other customary conditions set
forth in Annex I of the Merger Agreement. The consummation of the
Offer is not subject to any financing condition.
As soon as practicable after the time at which shares of
Medivation Stock are first accepted for payment and paid for under
the Offer (the "Acceptance Time"), subject to the satisfaction or
waiver of certain customary conditions set forth in the Merger
Agreement, Purchaser will be merged with and into Medivation, with
Medivation surviving the merger as a wholly owned subsidiary of
Pfizer (the "Merger"), pursuant to the procedure provided for under
Section 251(h) of the Delaware General Corporation Law without any
additional stockholder approvals. At the effective time of the
Merger (the "Effective Time"), each share of Medivation Stock
(other than treasury shares held by Medivation and any shares of
Medivation Stock owned by Pfizer or any of its subsidiaries or any
person who is entitled to and properly demands statutory appraisal
of his or her shares) will be converted into the right to receive
the Offer Price in cash, without interest (the "Merger
Consideration"), subject to any required withholding taxes.
At the Effective Time, each outstanding option to purchase
shares of Medivation Stock (each, a "Company Option") and stock
appreciation right with respect to shares of Medivation Stock
(each, a "Company SAR") will become fully vested and exercisable as
of immediately prior to such time and will be cancelled in exchange
for the right to receive a cash payment equal to the product of (i)
the excess, if any, of the Merger Consideration less the applicable
per share exercise price of such Company Option or base price of
such Company SAR, as applicable, multiplied by (ii) the number of
shares of Medivation Stock that are subject to such fully vested
Company Option or Company SAR, as applicable, as of immediately
prior to the Effective Time. At the Effective Time, each
outstanding restricted stock unit of Medivation will become fully
vested as of immediately prior to such time and will be cancelled
in exchange for the right to receive a cash payment equal to the
product of (i) the Merger Consideration multiplied by (ii) the
number of shares of Medivation Stock underlying such fully vested
restricted stock unit (with any such restricted stock units that
are subject to performance-based vesting being deemed earned
assuming achievement of all performance goals at the maximum levels
effective immediately prior to the Effective Time). Additionally,
each outstanding restricted share of Medivation will be cancelled
and converted into the right to receive an amount in cash equal to
the Merger Consideration. With respect to its Employee Stock
Purchase Plan ("ESPP"), Medivation will cause any outstanding
offering period under such plan to terminate as of the last
business day prior to the Acceptance Time, with outstanding rights
under such plan being exercised as of the Effective Time. Any
shares of Medivation Stock so purchased under the ESPP will be
canceled and converted into the right to receive an amount in cash
equal to the Merger Consideration.
The Merger Agreement contains representations, warranties and
covenants of the parties customary for a transaction of this
nature, including an agreement that, subject to certain exceptions,
the parties will use reasonable best efforts to cause the Offer and
the Merger to be consummated. Until the earlier of the termination
of the Merger Agreement and the Effective Time, Medivation has
agreed to operate its business in the ordinary course of business
consistent with past practice and has agreed to certain other
negative operating covenants, as set forth more fully in the Merger
Agreement.
The Merger Agreement also contains a "no-shop" provision that,
in general, restricts Medivation's ability to (i) solicit,
facilitate or encourage the making of Acquisition Proposals (as
defined in the Merger Agreement) or any inquiries regarding
Acquisition Proposals from third parties or (ii) provide non-public
information to or engage in discussions or negotiations with third
parties in connection with or in response to an Acquisition
Proposal. The no shop provision is subject to a "fiduciary out"
provision that
allows Medivation, under certain circumstances and in compliance
with certain obligations, to provide information and participate in
discussions and negotiations with respect to unsolicited
third-party acquisition proposals that constitute or would
reasonably be expected to lead to a Superior Offer (as defined in
the Merger Agreement) and, subject to compliance with certain
obligations, to terminate the Merger Agreement and accept a
Superior Offer upon payment to Pfizer of the termination fee
discussed below.
The Merger Agreement also includes customary termination
provisions for both Pfizer and Medivation, and provides that, in
connection with the termination of the Merger Agreement under
specified circumstances, including a termination by Medivation to
accept and enter into a definitive agreement with respect to a
Superior Offer, Medivation will pay Pfizer a termination fee of
$510,000,000.
The foregoing description of the Merger Agreement does not
purport to be complete, and is qualified in its entirety by
reference to the full text of the Merger Agreement, which is
attached hereto as Exhibit 2.1 and is incorporated herein by
reference.
A copy of the Merger Agreement has been included to provide
Pfizer stockholders and other security holders with information
regarding its terms and is not intended to provide any factual
information about Pfizer or Medivation. The representations,
warranties and covenants contained in the Merger Agreement have
been made solely for the purposes of the Merger Agreement and as of
specific dates; were solely for the benefit of the parties to the
Merger Agreement; are not intended as statements of fact to be
relied upon by Pfizer stockholders or other security holders, but
rather as a way of allocating the risk between the parties to the
Merger Agreement in the event the statements therein prove to be
inaccurate; have been modified or qualified by certain confidential
disclosures that were made between the parties in connection with
the negotiation of the Merger Agreement, which disclosures are not
reflected in the Merger Agreement itself; may no longer be true as
of a given date; and may apply standards of materiality in a way
that is different from what may be viewed as material by Pfizer
stockholders or other security holders. Pfizer stockholders or
other security holders are not third-party beneficiaries under the
Merger Agreement (except with respect to Medivation stockholders or
other security holders' right to receive the Merger Consideration
following the Effective Time) and should not rely on the
representations, warranties and covenants or any descriptions
thereof as characterizations of the actual state of facts or
condition of Pfizer, Purchaser or Medivation. Moreover, information
concerning the subject matter of the representations and warranties
may change after the date of the Merger Agreement, which subsequent
information may or may not be fully reflected in Pfizer's or
Medivation's public disclosures.
The full text of this SEC filing can be retrieved at:
http://www.sec.gov/Archives/edgar/data/78003/000119312516686937/d57934d8k.htm
Any exhibits and associated documents for this SEC filing can be
retrieved at:
http://www.sec.gov/Archives/edgar/data/78003/000119312516686937/0001193125-16-686937-index.htm
Public companies must file a Form 8-K, or current report, with
the SEC generally within four days of any event that could
materially affect a company's financial position or the value of
its shares.
(END) Dow Jones Newswires
August 22, 2016 08:27 ET (12:27 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024